Opinion|Videos|December 10, 2024
Insights on Managing Cough Symptoms in Patients With IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- Current IPF cough treatments are often inadequate, highlighting the need for improved therapeutic strategies and a deeper understanding of underlying mechanisms.
- The study identifies potential pathways for novel interventions, which could significantly enhance patient quality of life by targeting specific mechanisms.
Steven Nathan, MD, discusses how the findings from the study on oral nalbuphine extended release suggest that this treatment may offer an effective option for managing IPF-related cough, providing significant relief in terms of both frequency and severity, which could shift current management strategies by introducing a more targeted, pharmacologic approach to addressing one of the most challenging symptoms of IPF.
Advertisement
Episodes in this series
- What are your key takeaways from this study, and how might these findings impact the way IPF cough symptoms are currently managed?
Advertisement
Related to this article
CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
2
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5